Patents by Inventor Jiaping GAO

Jiaping GAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating HIV-HAART induced partial lipodystrophy with FGF21 protein variant FC fusion proteins
    Patent number: 11963999
    Abstract: The invention relates to the identification of new therapeutic methods for the FGF21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. insulin receptor mutation disorders (INSR disorders) and/or autoimmune insulin receptor disorders (Type B insulin Resistance)), defects in insulin production such as type 1 diabetes mellitus, mixed dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and other metabolic disorders, and various lipodystrophies such as HIV-HAART induced partial-lipodystrophy, and in reducing the mortality and morbidity of critically ill patients.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: April 23, 2024
    Assignee: Novartis AG
    Inventors: John Louis Diener, Jiaping Gao, Rick Jerome Schiebinger
  • LPL-GPIHBP1 FUSION POLYPEPTIDES
    Publication number: 20220025344
    Abstract: This disclosure relates to fusion polypeptides comprising lipoprotein lipase (LPL) and glycosylphosphatidylinositol-anchored High Density Lipoprotein-binding protein 1 (GPIHBP1). The disclosure also relates to uses of such fusion polypeptides in treating disease such as familial chylomicronemia syndrome (FCS).
    Type: Application
    Filed: November 25, 2019
    Publication date: January 27, 2022
    Inventors: Jiaping GAO, Amitabh NIMONKAR, John TRAUGER, Andrei Igorevich VOZNESENSKY, Stephen Craig WELDON
  • METHODS OF TREATING METABOLIC DISORDERS ASSOCIATED WITH LIPODYSTROPHIES AND DEFECTS IN INSULIN PRODUCTION OR SIGNALING
    Publication number: 20200101137
    Abstract: The invention relates to the identification of new therapeutic methods for the FGF21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. insulin receptor mutation disorders (INSR disorders) and/or autoimmune insulin receptor disorders (Type B insulin Resistance)), defects in insulin production such as type 1 diabetes mellitus, mixed dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and other metabolic disorders, and various lipodystrophies such as HIV-HAART induced partial-lipodystrophy, and in reducing the mortality and morbidity of critically ill patients.
    Type: Application
    Filed: May 9, 2019
    Publication date: April 2, 2020
    Applicant: Novartis AG
    Inventors: John Louis DIENER, Jiaping GAO, Rick Jerome SCHIEBINGER
  • METHODS OF TREATING METABOLIC DISORDERS ASSOCIATED WITH LIPODYSTROPHIES AND DEFECTS IN INSULIN PRODUCTION OR SIGNALING
    Publication number: 20170065678
    Abstract: The invention relates to the identification of new therapeutic methods for the FGF21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. insulin receptor mutation disorders (INSR disorders) and/or autoimmune insulin receptor disorders (Type B insulin Resistance)), defects in insulin production such as type 1 diabetes mellitus, mixed dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and other metabolic disorders, and various lipodystrophies such as HIV-HAART induced partial-lipodystrophy, and in reducing the mortality and morbidity of critically ill patients.
    Type: Application
    Filed: March 9, 2015
    Publication date: March 9, 2017
    Applicant: NOVARTIS AG
    Inventors: John Louis DIENER, Jiaping GAO, Rick Jerome SCHIEBINGER